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Objectives. We studied the clinical and genetic features of
familial hypertrophic cardiomyopathy (FHC) caused by an
Asp175Asn mutation in the alpha-tropomyosin gene in affected
subjects from three unrelated families.
Background. Correlation of genotype and phenotype has pro-
vided important information in FHC caused by beta-cardiac
myosin and cardiac troponin T mutations. Comparable analyses
of hypertrophic cardiomyopathy caused by alpha-tropomyosin
mutations have been hampered by the rarity of these genetic
defects.
Methods. The haplotypes of three kindreds with FHC due to an
alpha-tropomyosin gene mutation, Asp175Asn, were analyzed.
The cardiac histopathologic findings of this mutation are re-
ported. Distribution of left ventricular hypertrophy in affected
members was assessed by two-dimensional echocardiography, and
patient survival rates were compared.
Results. Genetic studies defined unique haplotypes in the three
families, demonstrating that independent mutations caused the
disease in each. The Asp175Asn mutation caused cardiac his-
topathologic findings of myocyte hypertrophy, disarray and re-
placement fibrosis. The severity and distribution of left ventricu-
lar hypertrophy varied considerably in affected members from the
three families (mean maximal wall thickness 6 SD: 24 6 4.5 mm
in anterior septum of Family DT; 15 6 2.7 mm in anterior septum
and free wall of Family DB; 18 6 2.1 mm in posterior septum of
Family MI), but survival was comparable and favorable.
Conclusions. Nucleotide residue 579 in the alpha-tropomyosin
gene may have increased susceptibility to mutation. On cardiac
histopathologic study, defects in this sarcomere thin filament
component are indistinguishable from other genetic etiologies of
hypertrophic cardiomyopathy. The Asp175Asn mutation can elicit
different morphologic responses, suggesting that the hypertrophic
phenotype is modulated not by genetic etiologic factors alone. In
contrast, prognosis reflected genotype; near normal life expect-
ancy is found in hypertrophic cardiomyopathy caused by the
alpha-tropomyosin mutation Asp175Asn.
(J Am Coll Cardiol 1997;29:635–40)
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Familial hypertrophic cardiomyopathy (FHC) can be caused
by a mutation in cardiac troponin T (1), cardiac myosin binding
protein C (2,3), beta cardiac myosin heavy chain (4,5), alpha-
tropomyosin (1) and essential or regulatory light chains (6).
Assessment of the phenotype associated with each mutation in
these disease genes has clarified the substantial clinical diver-
sity exhibited by patients with this disorder. That is, some beta
cardiac myosin heavy chain mutations (i.e., Arg403Gln) and
cardiac troponin T mutations are associated with significant
premature death (5,7), whereas life expectancy appears normal
(5) with other beta cardiac myosin heavy chain mutations (i.e.,
Val606Met). The morphologic response produced by these
mutations may also show some correlation with genotype; in
general, cardiac troponin T mutations produce less cardiac
hypertrophy (7) than beta cardiac myosin heavy chain muta-
tions (8).
Alpha-tropomyosin is a component of sarcomere thin fila-
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ments, and that is abundantly expressed in cardiac and skeletal
muscle. Although more than 50 different gene mutations have
been demonstrated to cause FHC, only three of these
(Ala63Val, Glu180Gly and Asp175Asn) occur in alpha-
tropomyosin (1,9,10). Limited clinical information has
emerged regarding the clinical consequences of these muta-
tions. We report a newly ascertained family (DT) with FHC
due to the alpha-tropomyosin mutation Asp175Asn. The car-
diac histopathologic findings of this mutation were comparable
to those observed in patients with FHC mutations in thick
filament proteins. Haplotype analysis of family DT and two
other families (DB and MI) bearing the alpha-tropomyosin
mutation Asp175Asn indicated that in each the gene defect
arose independently. We suggest that the recurrent finding of
a G3A transition in exon 5 may reflect increased vulnerability
to mutagenesis of alpha-tropomyosin residue 579. The mor-
phologic expression and clinical outcomes were compared in
affected members of these families. We conclude that although
the hypertrophic response elicited by the alpha-tropomyosin
mutation Asp175Asn is variable, the FHC caused by this gene
defect is associated with a favorable prognosis.
Methods
Clinical studies. All studies were performed in accordance
with institutional review committees at the Abbott-Northwestern
Hospital in Minneapolis, Ospedali Galliera in Genoa and
Brigham and Women’s Hospital. Familial hypertrophic cardio-
myopathy affection status was ascertained in all family mem-
bers by history, physical examination, 12-lead electrocardio-
gram and two-dimensional echocardiogram, performed as
described previously (8,10). Affection status was ascertained
without knowledge of genotype. The distribution and pattern
of left ventricular hypertrophy was assessed by measurement of
wall thickness in four segments of the left ventricle (11).
Genetic studies. Linkage analyses were performed in fam-
ilies using genomic DNA extracted from peripheral blood.
Polymorphic loci within or flanking known FHC disease genes
on chromosome 1 (1), 7 (12), 11 (2), 14 (5) and 15 (1) were
amplified using the polymerase chain reaction as described.
Logarithm of the odds scores were calculated using the
MLINK program, assuming a disease penetrance of 0.95%.
Haplotype analyses were performed using an intragenic
short-tandem repeat polymorphism (HTMaCA) within the
alpha-tropomyosin gene (1) and nearby flanking polymorphic
locus D15S108 (13).
The Asp175Asn mutation was identified after polymerase
chain reaction amplification of exon 5 from genomic DNA
extracted from peripheral blood (1) or from a paraffin-
embedded tissue sample (14) of ventricular muscle obtained at
postmortem examination of one individual. The nucleotide
sequence was determined using the Cyclist Taq DNA Sequenc-
ing Kit (Stratagene) following the manufacturer’s instruction,
except that the primer was end-labeled with phosphate-32
gamma-adenosine triphosphate.
Results
Clinical findings. Family DT. Ten members of Family DT
(Fig. 1) had FHC. Diagnosis was based on clinical studies
(Table 1) in eight individuals and at necropsy in two individ-
uals. Individual I-1 died suddenly at age 69 years; individual
II-2 died of abdominal hemorrhage and advanced cirrhosis at
age 51 years. Autopsy revealed cardiomegaly in each patient
(600 g in I-1; 450 g in II-2) and left ventricular hypertrophy.
Cardiac histologic examination (Fig. 2, A and B) demonstrated
marked myocyte hypertrophy and focal disarray; interstitial
fibrosis was prevalent.
Two-dimensional echocardiograms of the eight surviving
patients showed left ventricular hypertrophy (left ventricular
wall thickness $18 mm in each individual; mean [6 SD] 24 6
4.5 mm), which was particularly marked ($28 mm) in four
individuals. The distribution of left ventricular hypertrophy
was generally uniform in the family members and predomi-
nantly involved the anterior septum (Fig. 3A). Systolic anterior
motion of the mitral valve was present in two patients, mild in
one and severe (with mitral-septal contact producing marked
dynamic outflow obstruction) in the other.
Abbreviations and Acronyms
Ala63Val 5 alanine (residue 63) converted to valine
Arg92Gln 5 arginine (residue 92) converted to glutamine
Arg403Gln 5 arginine (residue 403) converted to glutamine
Arg453Cys 5 arginine (residue 453) converted to cysteine
Asp175Asn 5 aspartic acid (residue 175) converted to asparagine
FHC 5 familial hypertrophic cardiomyopathy
G3A 5 nucleotide residue guanine converted to adenine
Glu180Gly 5 glutamic acid (residue 180) converted to glycine
Val606Met 5 valine (residue 606) converted to methionine
Figure 1. Pedigree of Family DT and detection of the alpha-
tropomyosin gene mutation Asp175Asn in affected members. Clinical
affection status is shown: solid symbols 5 affected; open symbols 5
unaffected. Deceased individuals are indicated by a slash. The dideoxy
adenosine triphosphate sequence reactions of a portion of exon 5 is
shown below the pedigree. The G3A transition at residue 579 is
indicated by the arrow. Note that all clinically affected subjects, but
none of the clinically unaffected family members, carry the mutation.
Squares indicate male gender; circles indicate female gender; slashed
symbols indicate deceased individuals.
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Family DB. Three members of Family DB were affected
(Table 1) and surviving. No FHC-related deaths had occurred
in this family. Individual III-2 had one syncopal episode and an
episode of nonsustained ventricular tachycardia associated
with presyncope. He was treated with amiodarone and has
remained asymptomatic for longer than 5 years. His two sons
are also asymptomatic.
Left ventricular hypertrophy was mild in Family DB (max-
imal left ventricular wall thickness #18 mm; mean [6 SD]
156 2.7 mm) and predominantly involved the anterior septum
and contiguous portions of the lateral free wall (Fig. 3B). Mild
systolic anterior motion of the mitral valve was present in
patients III-2 and IV-2, but was insufficient to produce left
ventricular outflow obstruction.
Family MI. Six of eight affected members of Family MI
were asymptomatic or mildly symptomatic. Two individuals
had severe symptoms: individual IV-3 underwent a myotomy-
myectomy operation at age 12 years and currently has only
mild symptoms; individual IV-2 was successfully resuscitated
from cardiac arrest, which occurred concurrently with a fall at
age 18 years—he remains asymptomatic.
Two-dimensional echocardiograms were available in seven
affected members of Family MI. The maximal left ventricular
wall thickness ranged from 14 to 20 mm (mean [6 SD] 18 6
2.1) and predominantly involved the posterior septum in four
patients. Systolic anterior motion of the mitral valve was
present in three family members, mild in two and severe in one
(IV-3).
The composite disease phenotype exhibited by all affected
individuals from these three families included a spectrum of
clinical findings but general clinical stability. Eighteen (85%)
of the 21 affected individuals had mild or absent symptoms.
Table 1. Clinical Features of Familial Hypertrophic Cardiomyopathy in 21 Individuals With the Alpha-Tropomyosin Gene
Mutation Asp175Asn
Patients
Age (yr)/
Gender
NYHA
FC
Clinical
Profile*
Echocardiography Electrocardiography
Ant.
VS†
(mm)
Post.
VS†
(mm)
ALFW†
(mm)
Maximal
LVWT SAM
LVID
(mm)
LA
(mm)
T Wave
Inversion
Inferior or
Lateral Qs LVH
Family DT
I-1 71/M ? COPD; unexplained
death
NA NA NA NA NA NA NA NA NA NA
II-1 61/M II Syncope; DOE;
CAD
28 — — 28 0 46 46 1 2 2
II-2 51/M I Hemorrhage NA NA NA NA NA NA NA NA NA NA
II-3 66/F I Syncope 12 22 — 22 0 43 37 1 2 2
II-6 58/M I — 18 — — 18 0 47 54 1 1 2
III-1 38/F III DOE; CP; DDD
pacemaker
18 18 17 18 Severe: gradient
.70 mm Hg
40 39 Pacemaker 2 2
III-4 33/F II — 23 23 — 23 0 53 40 1 2 2
III-7 32/M I NSVT 28 22 — 28 Mild 48 45 1 2 1
III-6 30/F I — 28 18 — 28 0 43 26 1 1 2
III-8 26/M II CP; DOE 28 21 — 28 0 42 30 1 2 1
Family DB
III-2 55/M I Syncope 18 — 18 18 Mild 48 40 1 2 2
IV-1 23/M I — 14 — 14 14 Mild 48 40 2 1 2
IV-3 17/M I — 13 — 13 13 0 39 33 1 1 2
Family MI
II-4 79/F II CP; CAD/AMI;
high BP
15 17 17 17 0 48 45 1 2 2
II-7 78/F II High BP — 19 — 19 0 41 40 1 1 1
III-1 55/M I High BP — 20 — 20 0 48 45 1 2 1
III-4 45/M II Low BP 20 12 — 20 Mild 43 44 2 2 2
III-6 44/M I — 14 — — 14 — 46 46 2 1 1
III-10 45/F III Presyncope;
myectomy
12 18 — 18 Mild 44 44 Pacemaker 2 2
IV-2 18/M I SCD‡ — 19 — 19 — 50 34 1 2 1
IV-3 21/F III Myectomy NA NA NA NA NA NA NA NA NA NA
*Details of patients’ clinical profiles are provided in the text. †Wall thickness measurements are provided only for left ventricular segments judged to be
hypertrophied. ‡Etiology unclear; sudden cardiac death occurred concurrent with trauma. ALFW5 anterolateral free wall; AMI5 acute myocardial infarction; Ant.5
anterior; BP 5 blood pressure; CAD 5 coronary artery disease; COPD 5 chronic obstructive pulmonary disease; CP 5 chest pain; DOE 5 dyspnea on exertion; F 5
female; FC 5 functional class; LA 5 left atrium; LVH 5 left ventricular hypertrophy; LVID 5 left ventricular internal diastolic dimension; LVWT 5 left ventricular
wall thickness; M 5 male; NA 5 not applicable; NSVT 5 nonsustained ventricular tachycardia; NYHA 5 New York Heart Association; Post. 5 posterior; Qs 5 Q
waves; SAM 5 systolic anterior motion of mitral valve; SCD 5 sudden cardiac death; VS 5 ventricular septum.
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Electrocardiograms frequently showed deep inferolateral Q
waves, anterolateral T wave inversions and left ventricular
hypertrophy. Two-dimensional echocardiograms demon-
strated nonobstructive FHC in most individuals; a rest outflow
tract obstruction was present in ,15% of individuals. Longi-
tudinal studies, available in only a subset of affected family
members, demonstrated no evolution of cardiac hypertrophy
into cardiac dilation.
Genetic studies. Linkage analyses in Family DT excluded
the FHC genes on chromosomes 1, 7, 11 and 14 (data not
shown). Analyses with loci D15S108 and HTMa (1) were fully
informative and achieved logarithm of odds scores .3.0 (3.08
and 3.10, respectively), suggesting that FHC in this family was
caused by an alpha-tropomyosin mutation. Genomic DNA
from two affected individuals of Family DT was amplified by
PCR using intronic primers (4) flanking exons of the alpha-
tropomyosin gene. Polymerase chain reaction products were
sequenced (see Methods). A G3A transition was identified in
exon 5, which replaces the normal asparagine (residue 175)
with an aspartic acid. Exon 5 was then amplified from DNA
samples of all family members and sequenced; the G3A
mutation was identified in all clinically affected, but not in
clinically unaffected, members of Family DT.
The alpha-tropomyosin mutation Asp175Asn had been
previously demonstrated to cause FHC in affected members of
Families MI (1) and DB (10). A de novo mutation occurred
recently in Family DB (10). To determine whether the gene
defect in the two other families occurred because of a founder
mutation in an unidentified common ancestor, or because the
mutation arose independently in each family, the haplotypes
that segregated with the mutated allele were compared. The
haplotypes identified by polymorphisms HTMaCA and
D15S108 (Table 2) were unique in each family, indicating that
an independent mutation occurred in each family at alpha-
tropomyosin nucleotide residue 579.
Analysis of survival. The life expectancy associated with
the Asp175Asn mutation was assessed in the 21 clinically
affected members of the three combined families. A conserva-
tive approach was used in assessing disease-related deaths: DT
family member I-1, who died unexpectedly of an unknown
cause, and MI family member IV-2, who was resuscitated from
Figure 2. A comparison of the cardiac histopathologic findings observed
with the alpha-tropomyosin gene mutation Asp175Asn and the beta
cardiac myosin heavy chain gene mutation Arg719Trp. Hematoxylin-
eosin staining of postmortem myocardial sections from individuals I-1
(A) and II-2 (B) of Family DT and of the explanted heart from an
affected member of Family 101 (C) (15) reveals myocyte disarray,
myocyte hypertrophy and interstitial fibrosis. (Magnification 3 100,
reduced by 35%.)
Figure 3. Echocardiographic images showing diverse morphologic
expression of hypertrophic cardiomyopathy caused by the alpha-
tropomyosin mutation Asp175Asn. A, Individual III-6 (Family DT)
exhibits marked hypertrophy (i.e., 28 mm) of the distal anterior
ventricular septum (VS). Ao 5 aorta; LA 5 left atrium; LV 5 left
ventricle; PW 5 posterior free wall. B, Individual IV-3 (Family DB)
has mild left ventricular hypertrophy (i.e., 13 mm) involving the
anterior ventricular septum (VS) and a contiguous portion of the
anterior free wall (FW). (Calibration dots in A and large markings in
B are 10 mm apart.)
Table 2. Disease-Gene Haplotypes in Three Families With Familial
Hypertrophic Cardiomyopathy Caused by the Alpha-Tropomyosin
Gene Mutation Asp175Asn
Family
Polymorphism
HTMaCA D15S108
DT 3 3
DB 2 3
MI 3 1
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sudden cardiac death, were scored as deceased. The product-
limit survival curve (Fig. 4) substantiated that prognosis in
FHC due to the alpha-tropomyosin mutation Asp175Asn was
favorable. There were significantly fewer FHC-related deaths
from the Asp175Asn mutation than those deaths from FHC
caused by the beta cardiac myosin heavy chain mutation
Arg403Gln (p , 0.002) or the cardiac troponin T mutation
Arg92Gln (p , 0.003). Survival was comparable to the benign
(5,15) beta cardiac myosin heavy chain mutation Val606Met.
Discussion
Although alpha-tropomyosin gene mutations account for
,5% of FHC, we have identified three families in which a
G3A mutation at nucleotide residue 579 arose indepen-
dently. Phenotypic analyses of these families have demon-
strated that 1) the cardiac histopathologic findings associated
with an FHC gene encoding a thin filament component does
not differ from that seen with mutated proteins of the sar-
comere thick filaments; 2) the hypertrophic response elicited
by an FHC gene mutation is dependent on multiple factors;
and 3) prognosis is favorable in FHC due to the alpha-
tropomyosin gene mutation Asp175Asn.
Independent alpha-tropomyosin Asp175Asn mutations. In
addition to the families described in this report, the
Asp175Asn mutation has also been reported as a cause of FHC
in a family from Japan (9). Although haplotype analyses have
not been performed to formally exclude a founding mutation
shared by the three families studied herein and the Japanese
family, the distinct ethnic backgrounds of all four families
makes this unlikely. We suggest that the Asp175Asn mutation
has also occurred independently in this fourth family, and we
speculate that the high incidence of the Asp175Asn substitu-
tion may indicate an increased tendency to mutation of
guanine residue 579 in the alpha-tropomyosin gene. This
residue is a component of a CpG dinucleotide, which has been
previously recognized to have increased susceptibility to mu-
tagenesis within the genome (16). However, because the
dinucleotide CpG also occurs elsewhere within the alpha-
tropomyosin gene, it is likely that identification of this FHC
mutation is enhanced by phenotype selection, because this
protein is expressed not only in the heart, but also in all striated
muscles (17). Hence, we conclude not only that alpha-
tropomyosin residue 579 is a mutational hot spot, but that the
normally encoded amino acid residue Asp175 may be of major
importance for the function of alpha-tropomyosin in the heart.
Alpha-tropomyosin Asp175Asn and FHC phenotype. In
1960, Hollman et al. (18) reported the cardiac histopathologic
findings of FHC. Subsequent genetic studies of this family
identified the causal mutation (Arg453Cys) (5) in the beta
cardiac myosin heavy chain gene. Because there have been few
other examples of FHC cardiac histopathology for which a
genetic etiology has been defined, we wondered if the histo-
logic manifestations of FHC varied with genotype. FHC mu-
tations (1) have been identified in components of sarcomere
thick filaments (i.e., beta cardiac myosin heavy chain) and
components of sarcomere thin filaments (i.e., cardiac troponin
T and alpha-tropomyosin). Figure 2 compares the cardiac
histopathology of the alpha-tropomyosin mutation Asp175Asn
with that found in FHC caused by the beta cardiac myosin
heavy chain gene mutation Arg719Trp (15). There is marked
similarity in the severity of myocyte hypertrophy, disarray and
replacement fibrosis found in FHC caused by defects in
sarcomere thin or thick filament proteins. We conclude that
common cardiac histopathologic findings can occur in FHC
caused by different genetic etiologies.
Varying penetrance has been previously reported for FHC
due to different gene defects, with a high penetrance (;95%)
for beta cardiac myosin heavy chain mutations and a lower
penetrance (75%) for cardiac troponin T gene defects (5,7,19).
In the three families described in this report, all adults fulfilled
echocardiographic diagnostic criteria for FHC, which implies
that the alpha-tropomyosin mutation Asp175Asn is fully pen-
etrant in adulthood.
Although all affected adults had cardiac hypertrophy, left
ventricular morphology differed substantially among affected
individuals from three pedigrees with an identical alpha-
tropomyosin mutation. Marked hypertrophy was demonstrated
in Family DT, moderate hypertrophy in Family MI and mild
hypertrophy in Family DB (Table 1 and Figure 3). Differences
in the magnitude of the hypertrophic response was accompa-
Figure 4. A comparison of Kaplan-Meier product-limit curves for
survival in patients with familial hypertrophic cardiomyopathy caused
by the alpha-tropomyosin mutation Asp175Asn and other sarcomere
gene mutations. Survival of affected individuals was similar in Families
DT, DB and MI (data not shown). Survival data were combined and
plotted for all 21 affected members of these three families. Survival of
patients with familial hypertrophic cardiomyopathy due to the alpha-
tropomyosin mutation Asp175Asn was similar to that observed in
familial hypertrophic cardiomyopathy due to the beta cardiac myosin
heavy chain mutation Val606Met, and significantly better than survival
with the beta cardiac myosin heavy chain mutation Arg403Gln or
cardiac troponin T Arg92Gln mutation (p , 0.002 and p , 0.003,
respectively).
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nied by differences in distribution: hypertrophy predominantly
involved the anterior ventricular septum (Family DT) or the
posterior portion of the septum (Family MI) or the anterior
septum and contiguous free wall (Family DB). We conclude
that interactions between the alpha-tropomyosin mutation and
other genes and environment can substantially influence the
morphologic expression of the disease.
Despite the phenotypic differences observed in these three
families, the survival of affected individuals was similar. The
product-limit survival curve showed a favorable prognosis (Fig.
4) with survival significantly longer than that previously re-
ported for “malignant” beta cardiac myosin heavy chain mu-
tations (5) or cardiac troponin T mutations (7). Life expect-
ancy with the alpha-tropomyosin gene mutation Asp175Asn
was similar to that associated with beta cardiac myosin heavy
chain mutations regarded as benign (5,15).
Many issues regarding the genetics of FHC and the corre-
lation between genetic alterations and clinical expression of
the disease (19,20) remain unresolved. Comparison of the
phenotype exhibited by unrelated, affected individuals with an
identical FHC mutation provides a unique opportunity to
discriminate between clinical findings caused by a particular
genetic defect and findings that are influenced by background
genes, the environment, or both. Determination of the entire
spectrum of genetic and nongenetic factors that influence FHC
should improve appropriate risk stratification and manage-
ment of affected individuals.
We thank Milena Ruscillo for secretarial assistance. We are grateful to the family
members for participating in these studies.
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